Vigil Neuroscience (NASDAQ:VIGL) Price Target Raised to $24.00 at Wedbush

Vigil Neuroscience (NASDAQ:VIGL) had its price objective upped by analysts at Wedbush from $23.00 to $24.00 in a research note issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock.

A number of other equities research analysts also recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $17.00 price target on shares of Vigil Neuroscience in a research report on Friday. Guggenheim cut their price target on Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.80.

Vigil Neuroscience Stock Up 2.5 %

Shares of NASDAQ VIGL traded up $0.09 during trading on Friday, reaching $3.66. The company had a trading volume of 4,519 shares, compared to its average volume of 236,440. The company’s fifty day moving average price is $3.58 and its 200-day moving average price is $3.63. Vigil Neuroscience has a 12 month low of $2.47 and a 12 month high of $6.98. The stock has a market cap of $145.11 million, a P/E ratio of -1.70 and a beta of 1.92.

Vigil Neuroscience (NASDAQ:VIGL) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.02. As a group, equities analysts predict that Vigil Neuroscience will post -2.15 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of VIGL. Acadian Asset Management LLC purchased a new position in Vigil Neuroscience during the second quarter valued at approximately $26,000. Renaissance Technologies LLC grew its holdings in Vigil Neuroscience by 19.2% in the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock valued at $286,000 after purchasing an additional 11,536 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Vigil Neuroscience in the second quarter valued at approximately $87,000. Vanguard Group Inc. grew its holdings in Vigil Neuroscience by 11.9% in the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock valued at $3,050,000 after purchasing an additional 95,276 shares during the period. Finally, Ensign Peak Advisors Inc grew its holdings in Vigil Neuroscience by 72.8% in the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock valued at $1,580,000 after purchasing an additional 166,442 shares during the period. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.